Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
• By Brian Marson
One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
